Healthcare decision-making for tumour-agnostic therapies in Europe: lessons learned
Open Access
- 23 May 2024
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 29 (7) , 104031
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Pembrolizumab for allJournal of Cancer Research and Clinical Oncology, 2022
- Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆Annals of Oncology, 2021
- Developing a Framework for the Health Technology Assessment of Histology-independent Precision Oncology TherapiesApplied Health Economics and Health Policy, 2021
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)Annals of Oncology, 2020
- Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma NetworkAnnals of Oncology, 2020
- Developing Drugs for Tissue‐Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision MedicineClinical Pharmacology & Therapeutics, 2020
- Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and EuropeClinical Pharmacology & Therapeutics, 2020
- Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved DrugsClinical Pharmacology & Therapeutics, 2018
- The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomasCancer, 2018